Advanced search
Publication Cover
Journal of Asthma and Allergy Volume 13, 2020 - Issue
Submit an article Journal homepage
144
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma

Jared Silver1 US Medical Affairs, GSK, Research Triangle Park, NC, USAORCID Iconhttps://orcid.org/0000-0002-7838-0985View further author information
ORCID Icon,
Michael Bogart1 US Medical Affairs, GSK, Research Triangle Park, NC, USAView further author information
,
Elizabeth Packnett2 Life Sciences, IBM Watson Health, Bethesda, MD, USAView further author information
,
Juan Wu2 Life Sciences, IBM Watson Health, Bethesda, MD, USAView further author information
,
Donna McMorrow2 Life Sciences, IBM Watson Health, Bethesda, MD, USAView further author information
&
Beth Hahn1 US Medical Affairs, GSK, Research Triangle Park, NC, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7396-9336View further author information
ORCID Icon
Pages 689-699 | Published online: 16 Dec 2020

References

  • GINA. Global initiative for asthma. Global strategy for asthma management and prevention; 6 2019 Available from: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Accessed 12 2019.
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi:10.1183/09031936.0020201324337046
  • Chastek B, Korrer S, Nagar SP, et al. Economic burden of illness among patients with severe asthma in a managed care setting. J Manag Care Spec Pharm. 2016;22(7):848–861.27348285
  • Zeiger RS, Schatz M, Dalal AA, et al. Utilization and costs of severe uncontrolled asthma in a managed-care setting. J Allergy Clin Immunol Pract. 2016;4(1):120–129 e123. doi:10.1016/j.jaip.2015.08.00326439182
  • Omachi TA, Iribarren C, Sarkar U, et al. Risk factors for death in adults with severe asthma. Ann Allergy Asthma Immunol. 2008;101(2):130–136. doi:10.1016/S1081-1206(10)60200-118727467
  • Buhl R, Humbert M, Bjermer L, et al. Severe eosinophilic asthma: a roadmap to consensus. Eur Respir J. 2017;49:5. doi:10.1183/13993003.00634-2017
  • Sarnes E, Crofford L, Watson M, Dennis G, Kan H, Bass D. Incidence and US costs of corticosteroid-associated adverse events: a systematic literature review. Clin Ther. 2011;33(10):1413–1432. doi:10.1016/j.clinthera.2011.09.00921999885
  • Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S17602630214247
  • Krings JG, McGregor MC, Bacharier LB, Castro M. Biologics for severe asthma: treatment-specific effects are important in choosing a specific agent. J Allergy Clin Immunol Pract. 2019;7(5):1379–1392. doi:10.1016/j.jaip.2019.03.00831076056
  • Nucala GSK. Prescribing information; 9 2019 Available from: https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Nucala/pdf/NUCALA-PI-PIL.PDF. Accessed 12 2019.
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa140329125199060
  • Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X22901886
  • Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X28395936
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa140329025199059
  • Caminati M, Cegolon L, Vianello A, et al. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. Expert Rev Respir Med. 2019;13(12):1205–1212. doi:10.1080/17476348.2019.167673431592700
  • Montero-Perez O, Contreras-Rey MB, Sanchez-Gomez E. Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice. Drugs Context. 2019;8:212584. doi:10.7573/dic.21258431191705
  • Strauss RA, Jawhari N. Mepolizumab in the treatment of severe eosinophilic asthma: results from a physician in the field. Ann Allergy Asthma Immunol. 2018;121(1):121–123. doi:10.1016/j.anai.2018.04.01629684570
  • JP OH L, Bogart M, Packnett ER, Manjelievskaia J, Bell CF, Hahn B. Real-world effectiveness of mepolizumab in patients with severe asthma: an examination of exacerbations and costs. J Asthma Allergy. 2020;13:77–87. doi:10.2147/JAA.S23660932099413
  • Liu D, Ahmet A, Ward L, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30. doi:10.1186/1710-1492-9-3023947590
  • Mundell L, Lindemann R, Douglas J. Monitoring long-term oral corticosteroids. BMJ Open Qual. 2017;6(2):e000209. doi:10.1136/bmjoq-2017-000209
  • Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j141528404617
  • Pavord ID, Beasley R, Agusti A, et al. After asthma: redefining airways diseases. Lancet. 2018;391(10118):350–400. doi:10.1016/S0140-6736(17)30879-628911920
  • Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq43321330339

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.